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Abstract 
Background & Aims: Liver regeneration requires functional liver macrophages, which provide an 
immune barrier that is compromised following liver injury. Numbers of liver macrophages are 
controlled by macrophage colony stimulating factor (CSF1). We examined the prognostic significance 
of serum level of CSF1 in patients with acute liver injury and studied its effects in mice. 
Methods: We measured levels of CSF1 in serum samples collected from 55 patients who underwent 
partial hepatectomy at the Royal Infirmary Edinburgh between December 2012 and October 2013, as 
well as from 78 patients with acetaminophen-induced acute liver failure admitted to the Royal Infirmary 
Edinburgh or the University of Kansas Medical Centre. We studied the effects of increased levels of 
CSF1 in uninjured mice that express wild-type CSF1 receptor or a constitutive or inducible CSF1 
receptor reporter, as well as in Ccr2–/– mice; we performed fate-tracing experiments using bone marrow 
chimeras. We gave CSF1-Fc to mice following partial hepatectomy and acetaminophen intoxication, 
and measured regenerative parameters and innate immunity by clearance of fluorescent microbeads and 
bacterial particles.  
 Results: Serum levels of CSF1 increased in patients undergoing liver surgery in proportion to the 
extent of liver resected. In patients with acetaminophen-induced acute liver failure, low serum level of 
CSF1 was associated with increased mortality. In mice, administration of CSF1-Fc promoted hepatic 
macrophage accumulation via proliferation of resident macrophages and recruitment of monocytes. 
CSF1-Fc also promoted trans-differentiation of infiltrating monocytes into cells with a hepatic 
macrophage phenotype. CSF1-Fc increased innate immunity in mice following partial hepatectomy or 
acetaminophen-induced injury, with resident hepatic macrophage  the main effector cell.  
Conclusions: Serum CSF1 appears to be a prognostic marker for patients with acute liver injury. CSF1 
might be developed as a therapeutic agent to restore innate immune function following liver injury. 
 
Keywords: drug-induced liver damage; clearance; immune response; M-CSF 
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Introduction 
The liver provides an essential immune barrier against gut-derived pathogens entering the portal 
circulation1. While surgical removal of liver tissue (partial hepatectomy) results in rapid compensatory 
upregulation of metabolic function, the liver’s innate immune capacity is markedly impaired2, 3. Acute 
toxic liver injury leads to widespread hepatocyte necrosis and compromises barrier function4. Changes 
in gut wall integrity associated with liver failure facilitate the translocation of gut-derived pathogens5.  
Consequently, sepsis is common in patients with liver failure and is strongly-associated with high 
mortality rates6, 7. Liver transplantation is the only effective therapy for life-threatening liver failure but 
active sepsis is contraindicated in transplantation. 
 
Hepatic macrophages mediate hepatic innate immune defence and promote hepatocyte proliferation 
following liver injury8, 9. Tissue macrophage numbers are controlled during development, and in the 
steady state, by macrophage colony stimulating factor (CSF1), which acts through a tyrosine kinase 
receptor, CSF1R10, 11. Csf1- deficient mice (op/op) have few tissue macrophages and impaired liver 
regeneration following partial hepatectomy12.  Hepatic macrophages control circulating CSF1 levels via 
receptor-mediated endocytosis through CSF1R13. In humans following living donor partial 
hepatectomy, elevated circulating CSF1 is associated with more rapid liver regrowth14. In acute toxic 
liver injury models, monocyte-derived macrophage recruitment is required for necrotic tissue 
resorption15. In human acute liver injury, hepatic macrophages are implicated in tissue repair and low 
monocyte counts are associated with mortality16, 17. Based upon these findings there is a strong rationale 
for exploring the potential of macrophage-based therapeutics to improve outcomes following acute liver 
injury.  
 
Here we demonstrate that high serum CSF1 is associated with survival in patients with ALF and 
outperforms previous markers of outcome in terms of discriminative ability. We demonstrate that CSF1 
administration in animal disease models promotes rapid recovery of innate immune function and hence 
has therapeutic potential in human liver failure.  
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Materials and Methods 
Human Work 
Ethical approval was obtained from the South East Scotland Research Ethics Committee (2) for patients 
undergoing PH at the Hepatobiliary Unit, Royal Infirmary Edinburgh, between December 2012 and 
October 2013. Liver failure was defined according to Schindl et al.7. For the acetaminophen induced 
acute liver failure (ALF) cohort, ethical approval was granted by the local human research ethics 
committee and informed consent obtained from all patients, or next of kin, before study entry. This 
study builds on previous analysis of this patient cohort by Antoine et al.18, representing 78 adult patients 
admitted to the Royal Infirmary Edinburgh, UK or the University of Kansas Medical Centre, USA with 
acute liver injury.  Serial patient samples from a second patient cohort were collected at admission to 
hospital (as opposed to admission to the specialist liver centre with acute liver failure)18.  Details of 
serum analyses are provided in the supplementary methods.  Primary hepatocytes were isolated from 
human liver tissue obtained from liver resection specimens immediately following surgery, with full 
informed consent and ethical approval from the relevant authorities (National Research Ethics Service 
REC reference: 11/NW/0327). See Supplementary Methods for assay details.  
 
Animal experiments 
Animal procedures were approved by the relevant institutional ethics committee (Albert Einstein 
College of Medicine, USA, University of Edinburgh, UK, and the University of Glasgow, UK) and 
adhered to the Animals (Scientific Procedures) Act 1986, UK and NIH guide for the Care of Laboratory 
Animals, USA. 8 -12 week male mice were used. CCR2–/–,C57Bl/6 and MacGreen mice (Tg(Csf1R-
GFP)Hume19 were bred and maintained under specific pathogen-free conditions. Tg(Csf1r-Mer2iCre)jwp 
were crossed to Rosa floxed stop tomato red and lineage tracing experiments performed as described20. 
Fate tracing bone marrow-derived monocytes was performed using a mouse chimera as previously 
described21. Wild type C57BL/6 mice were obtained from Charles River. Mice were randomly 
distributed and maintained on 12-hr light-dark cycle with feed ad libitum. 2/3 partial hepatectomy was 
performed as previously described22. Acetaminophen intoxication involved intraperitoneal 
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administration of 350mg/kg acetaminophen (Sigma Aldrich)23. Treatment group received 0.75mcg/g 
CSF1-Fc, prepared as described previously24 (control: PBS) administered subcutaneously immediately 
following partial hepatectomy or 12 hours following acetaminophen intoxication and subsequently 
every 24 hours for up to three further doses. Reagents and methodology for immunohistochemistry, 
flow cytometry, quantification of mRNA, phagocytosis assay and serum analyses are provided in the 
supplementary methods. 
 
Hepatocyte toxicity and metabolic assays 
Details of human and mouse hepatocyte toxicity and metabolic assays are provided in the 
Supplementary Methods.  
 
Statistics 
Statistical analysis was performed on Graphpad Prism V6.0, except logistic regression analyses which 
were conducted in R25. All data are presented as mean +/- standard error of the mean unless otherwise 
stated. Two tailed Student’s t test are used where appropriate to analyse parametric data. One-way and 
Two way ANOVA with Bonferroni adjustment are stated when used.  Human serum analyses and 
development of the logistic regression models were completed by a qualified statistician. Level of 
significance was set at p<0.05 for all analyses (figures *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). 
 
 
Results 
Serum CSF1 rises according to extent of partial hepatectomy and is associated with survival in 
acute liver failure 
 In a cohort of 55 patients undergoing up to 75% PH (cohort details: Supplementary Figure 1A) serum 
CSF1 was significantly elevated compared to healthy controls. There was a small reduction at day 1 
post surgery followed by a marked increase in CSF1 level by postoperative day 3 (Figure 1A). There 
was no correlation between serum CSF1 level and blood loss (Supplementary Figure 1B). The initial 
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fall in serum CSF1 level may be due to removal of tumour cells, which secrete CSF126. We hypothesized 
that the subsequent rise in serum CSF1 level might be produced by proliferating hepatocytes.  Due to 
the risks associated with liver biopsy in humans, we examined a mouse model of 2/3 PH CSF1 mRNA 
was unchanged following PH (Supplementary Figure 1C).  In the patient cohort the CSF1 increase was 
related to the extent of resection (Figure 1B). Two patients developed postoperative liver failure and 
both had serum CSF1 levels below the 25th percentile (Figure 1C; clinical details in Supplementary 
Figure 1D). 
 
We sampled serum from a large patient cohort with established acetaminophen-induced ALF on arrival 
at the specialist centre (cohort details: Supplementary Figure 2A)18. Assessment of ALF and 
requirement for liver transplantation is currently based on the validated modified King’s College 
Hospital (KCH) criteria which reflect poor clinical condition and likelihood of death. Low serum CSF1 
was significantly associated with patient deterioration to KCH criteria (Supplementary Figure 2B and 
C), and subsequent death or liver transplantation (Figure 2A). Regardless of final outcome, those 
patients with a Systemic Inflammatory Response Score (SIRS27) >2 had a significantly lower CSF1 
level (Supplementary Figure 2D). Serial samples in a separate patient cohort (details Supplementary 
Figure 2E), followed from first presentation to hospital, showed serum CSF1 levels continued to 
increase in patients whose liver regenerated, whereas CSF1 levels fell in those who deteriorated (Figure 
2B). In the livers removed from transplant recipients, CSF1 was detected in hepatocytes and non-
parenchymal cells (Supplementary Figure 2E).  Given the risks of liver biopsy, we used the mouse 
model to assess hepatic CSF1 gene expression. In contrast to PH, hepatic CSF1 mRNA expression 
increased significantly following acetaminophen intoxication peaking at Day 2 (Supplementary Figure 
2F).  
 
The current best available prognostic biomarker in ALF is serum acetyl-HMGB1 (high mobility group 
box-1)18. This DAMP (damage associated molecular patterns) is released from necrotic tissue and by 
activated immune cells in response to injury28. We assessed the discriminative ability of acetyl-
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HMGB1, alongside CSF1 and also established clinical measures including bilirubin, prothrombin time 
and ALT level using the receiver operator characteristic (ROC) curve (Figure 2C). Serum CSF1 and 
acetyl-HMGB1 demonstrate similar profiles, whereas bilirubin, PT, ALT and APACHEII score were 
of limited value. There was an inverse correlation between CSF1 and acetyl-HMGB1 (Figure 2D).  
When combined in a logistic regression model, only CSF1 showed significance (Figure 2E; 
Supplementary Figure 2F), indicating that serum CSF1 level was a better predictor of outcome than 
acetyl-HMGB1 (Supplementary Figure 2G and H). Figure 2F provides example CSF1 values with risk 
of death based on the ‘CSF1 alone’ model. 
 
Sustained CSF1R stimulation induces hepatic enlargement involving macrophage accumulation 
in mice 
The association of low serum CSF1 with poor prognosis in ALF provides a rationale for therapeutic 
use.  Some studies report that CSF1R is expressed outside the macrophage lineage29, 30. We therefore 
examined CSF1R expression using MacGreen mice, where eGFP is under the control of the Csf1r 
promoter19. Multiphoton ex vivo imaging of liver confirmed CSF1R expression limited to cells with 
tissue macrophage morphology (Figure 3A). To confirm this, we crossed Csf1r-Mer-Cre-Mer to 
Rosa26-LSL-dTom reporter mice to allow tamoxifen-induced labelling of CSF1R+ cells, as previously 
described20. Co-localisation of the pan-macrophage marker F4/80 confirmed that all dTomato+ cells 
(CSF1R+) cells belonged to the macrophage lineage (Figure 3B). These data are supported by 
expression profiling from the FANTOM5 consortium that show no detectable CSF1R mRNA in 
hepatocytes isolated from control, or regenerating, mouse liver or isolated human hepatocytes31. 
 
To assess the therapeutic potential of CSF1, we used the CSF1-Fc fusion protein, which overcomes the 
short half-life of CSF1 protein in vivo24.  CSF1-Fc treatment of mice promoted hepatic macrophage 
accumulation but the mechanisms were unclear24, 32. Six hours following CSF1-Fc administration to 
uninjured mice there was a marked upregulation of hepatic chemokines, particularly CCL2, CCL7 and 
CCL12, which are ligands for the CCR2 receptor and highly expressed by classical (Ly6C+) blood 
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monocytes (Figure 3C; array details Supplementary Figure 3A). After 4 days of CSF1-Fc treatment 
20% of the liver was composed of F4/80+ macrophages compared to 2% in steady state (Fig 3D). This 
macrophage accumulation initiated hepatocyte proliferation at day 424. Mechanisms of hepatocyte 
proliferation are multifactorial with an upregulation of many cytokines and chemokines associated with 
the inflammatory response24. Despite the induction of pro-inflammatory cytokine mRNA in the liver, 
serum ALT and AST were reduced with CSF1-Fc treatment, while bilirubin was unchanged (Fig 3F) 
and there was no hepatocyte apoptosis (Supplementary Fig 3B). The spleen increased in size although 
weight of other organs did not change (Supplementary Fig 3C and 3D).   
 
Macrophage accumulation involves in situ proliferation and CCR2-related infiltration 
Infiltrating monocyte-derived macrophages and tissue resident macrophages can be distinguished by 
relative expression of F4/80 and CD11b and may remain distinctly-regulated entities in steady state 
liver and following acetaminophen-induced injury20, 33-35. Following CSF1-Fc treatment, there was a 
two-fold increase in cells with a resident hepatic macrophage phenotype (F4/80hiCD11blo) and over a 
five-fold increase in the monocyte-derived infiltrating macrophages (F4/80loCD11bhi cells), consisting 
predominantly of Ly6Chi monocytes (Figure 4A). Both F4/80hiCD11blo and F4/80loCD11bhi cells 
proliferated markedly in situ following CSF1-Fc administration (Figure 4B; Supplementary Figure 4A 
and B).  Liver macrophages in the treated livers were fate-mapped using tissue-protected bone marrow 
chimeric mice, where only the hind legs of recipient CD45.1+CD45.2+ animals were irradiated before 
engraftment of congenic CD45.1+ bone marrow. In these animals, F4/80loCD11bhi macrophages and 
blood monocytes exhibited equivalent donor chimerism (Figure 4C). In PBS treated animals 
F4/80hi/CD11blo cells remained almost exclusively of host origin, consistent with their proposed tissue 
origin20, 33, 34.  However, following CSF1-Fc treatment, approximately 20% of the F4/80hi/CD11blo cells 
were derived from recruited cells. Thus, the increase in liver macrophages resulted from infiltration of 
monocytes, proliferation of infiltrating and resident cells as well as a minor role for differentiation of 
infiltrating macrophages into a resident macrophage phenotype. The only other cell population that 
increased significantly was eosinophils (Supplementary Figure 4C), which may have responded to 
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eosinophil chemoattractants CCL3, 4, 7 and 12, detected 6 hours following CSF1-Fc administration 
(Figure 3C).  
 
Ligands for the CCR2 receptor, which are potent monocyte chemoattractants, were upregulated early 
after CSF1-Fc administration (Figure 3A).   To examine the role of recruited monocytes, we tested 
CSF1-Fc administration on Ccr2–/– mice, hypothesizing that the mobilization and recruitment of 
infiltrating F4/80lo CD11bhi macrophages would be prevented since Ly6Chi monocytes are thought to 
depend upon CCR2 signals for release from the bone marrow and extravasation into inflamed tissues15, 
36. Surprisingly Ccr2–/– mice developed a pronounced Ly6Chi monocytosis following CSF1-Fc 
administration, indicating that CSF1 can overcome the CCR2 requirement for marrow release 
(Supplementary Figure 4D). Nevertheless, CSF1-Fc driven hepatic engraftment by infiltrating 
macrophages was reduced by CCR2 deficiency (Figure 4D). Accumulation of resident F4/80hiCD11blo 
macrophages was largely unaffected, consistent with local proliferation being the major means of 
expansion. The increase in eosinophils was unaffected by CCR2 deficiency.  CSF1-Fc treatment 
increased hepatic neutrophils in CCR2 deficiency (Supplementary Figure 4E), probably due to the 
deficit in infiltrating monocytes which regulate neutrophil activity35. Importantly, CCR2 deficiency 
prevented the increase in liver to body weight ratio observed in wild type mice following CSF1-Fc 
administration (Figure 4C). Although F4/80lo/CD11bhi macrophages are not completely dependent on 
CCR2 for mobilisation and trafficking to tissues, the data suggest the action of CSF1-Fc on monocyte-
derived rather than resident macrophages is the critical step promoting hepatic enlargement.  
 
 
CSF1-Fc treatment accelerates recovery of innate immune capacity following partial 
hepatectomy 
Patient survival depends upon the rapid restoration of liver macrophage functions to clear pathogenic 
material.  We therefore tested the effect of CSF1-Fc upon innate immune function in injury models.  
CSF1-Fc administration increased liver size over controls at 4 days following PH (Figure 5A). 
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Hepatocyte staining (CYPD2) per unit area (Supplementary Figure 5A) was reduced following CSF1-
Fc treatment, indicating the increased size was due to increased non-parenchymal cell accumulation.  
Peak hepatocyte proliferation (Day 2) was not increased by CSF1-Fc treatment (Figure 5B), although 
at later time points the macrophage accumulation did promote increased hepatocyte proliferation 
compared to controls. To confirm the role of endogenous CSF1 signalling, implied from studies of 
op/op mice12, we treated with a CSF1R kinase inhibitor (GW2580) or a blocking antibody against the 
CSF1 receptor (AFS98).  Both treatments reduced hepatocyte proliferation (Supplementary Figure 5b) 
and affected the expression of macrophage related cytokine and matrix remodelling genes associated 
with regeneration (Supplementary Figure 5C and 5D). 
Following PH, macrophages accumulated more rapidly in the liver of CSF1-Fc treated mice, involving 
both monocyte derived infiltration and proliferation (Figure 5C).  There was a corresponding elevation 
in genes encoding phagocytic receptors37, 38, such as MARCO (macrophage receptor with collagenous 
structure) and MSR1 (macrophage scavenger receptor 1, with a reciprocal reduction following CSF1 
blockade (Figure 5D).  To assess the impact on clearance of insoluble material and bacteria-derived 
particles, we injected fluorescent-labelled latex microbeads intravascularly. These were rapidly and 
selectively taken up by liver phagocytes . There was minimal uptake by the spleen, lung, kidney, brain, 
and circulating cellular populations (Supplementary Figure 5E-G). Multiphoton imaging of the Csf1r-
eGFP mouse liver confirmed that microbeads were phagocytosed by hepatic macrophages with CSF1-
Fc treatment causing enhanced clearance from the circulation (Figure 5E).  Ex vivo whole organ 
fluorescence imaging indicated this enhanced clearance capacity was clearly due to liver uptake (Figure 
5F). To extend these findings to potential pathogens, we used pH sensitive E. coli bioparticles which 
fluoresce when taken up into acidified vesicles and injected these into the portal vein (Figure 6A). 
CSF1-Fc treatment increased both internalisation capacity and the absolute yield of positive cells 
(Figure 6B).  Relatively few infiltrating monocyte-derived cells (F4/80lo CD11bhi) internalised the 
labelled E.coli, but CSF1-Fc treatment again increased the clearance capacity (Figure 6C).  The Ly6Clo 
monocyte population consistently showed a greater propensity for phagocytosis compared to the Ly6Chi 
population based on percentage of the populations phagocytosing the E.coli particles both in the control 
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and CSF1-Fc treated groups (Figure 6C). The resident F4/80hi CD11blo cells remained the dominant 
phagocyte in the liver (Figure 6D).   
 
The impact of CSF1-Fc on acetaminophen toxicity  
The predictive value of serum CSF1 levels in patients with ALF, and the ability of CSF1-Fc to promote 
regeneration and improve clearance functions, suggests therapeutic potential in acetaminophen toxicity. 
Macrophage accumulation, proliferation of resident macrophages and infiltration of monocyte-derived 
macrophages is essential for recovery and subsequent regeneration following acetaminophen 
administration to mice16, 35. Enhanced macrophage accumulation could facilitate recovery by rapidly 
clearing necrotic debris and restoring hepatic immune function.  We treated mice with CSF1-Fc 12 
hours following acetaminophen intoxication, the point of maximal injury39. CSF1-Fc treatment 
expanded the macrophage compartment and increased liver weight to body weight ratio (Figure 7A). 
CSF1-Fc increased macrophage accumulation at the area of necrosis (Figure 7B), without significantly 
increasing the affected area (Supplementary Figure 6A). In control treated animals there was a 
predominance of infiltrating monocytes relative to resident hepatic macrophages as previously 
described15, and both these populations were boosted by CSF1-Fc (Supplementary Figure 6B). 
Expression of mRNA for clearance receptors MARCO and MSR was enhanced in the livers of CSF1-
Fc treated animals (Figure 7C), associated with an increase in the phagocytic capacity of the liver 
detected using injected microbeads (Figure 7D). Despite the profound macrophage changes in the liver, 
serum cytokines were unaffected by CSF1-Fc treatment (Supplementary Figure 6C). Increased 
macrophage recruitment did not produce additional injury. Serum injury markers (ALT, Alk phos) 
decreased in CSF1-Fc treated mice, with reciprocal change following CSF1R blockade (Figure 7E; 
Supplementary 7F and G). These findings most likely reflect changes in the clearance of these enzymes 
by hepatic macrophages40 (Figure 7C). Serum albumin was reduced by CSF1-Fc treatment, likely a 
reflection of the pro-inflammatory state given hepatic albumin gene expression was unchanged from 
control (Supplementary Figure 6D). Serum total protein was also unchanged (Supplementary Figure 
6E). To further explore potential direct effects of CSF1-Fc on hepatocytes we assessed hepatocyte 
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viability and performed metabolic assays, which demonstrated no direct effect of CSF1-Fc on either 
mouse or human hepatocytes (Supplementary Figure 7A and B). Further, following acetaminophen 
intoxication in mice, there was no change in cytochrome p-450 activity assessed by CYP2E1 expression 
with CSF1-Fc treatment (Supplementary Figure 7C). 
 
Discussion  
We have demonstrated a clear association between reduced serum CSF1 level and poor outcome in 
acute liver failure in humans. CSF1-Fc treatment produced hepatic macrophage accumulation through 
in situ macrophage proliferation and recruitment of monocyte-derived cells in mouse models.  Resident 
macrophages in the mouse are largely maintained through self-renewal33. Fate mapping of 
hematopoietic cells indicated that CSF1-Fc can also drive conversion of circulating monocytes to cells 
of a resident macrophage phenotype. This novel finding demonstrates the plasticity in the resident and 
infiltrating macrophage compartments and provides new evidence that bone marrow derived 
macrophages can contribute to the resident macrophage population given appropriate stimuli.   
 
CSF1-Fc driven hepatic macrophage accumulation enhanced innate immune capacity in mouse models 
of liver injury. Following PH, the therapeutic requirement to optimise liver function and boost 
regeneration must be weighed against the potential to promote cancer recurrence. Malignant tumours 
can themselves produce CSF1 which mediates macrophage accumulation, supporting tumour growth41.  
Indeed, our series of preoperative patients with cancer in situ had elevated serum CSF1. However, 
effective elimination of circulating tumour cells, which are indicative of recurrence, requires hepatic 
macrophages which depend upon CSF110, 42, 43. The ability to enhance the innate immune capacity of 
the liver by increasing hepatic macrophage density may be valuable from an antimicrobial standpoint 
and may theoretically reduce cancer recurrence rates which can reach 60% 44.  
 
ALF represents a different clinical challenge to PH. The low serum CSF1 in those who required liver 
transplantation or died in our patient cohort is consistent with the monocytopenia described in ALF, 
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particularly given the persistence of monocyte precursors in the bone marrow16, 17. Monocytes express 
low levels of HLA-DR in ALF which can impair the response to sepsis17. Together with our results, 
these findings indicate that supplementary CSF1 therapy in the setting of low serum CSF1 might 
facilitate recovery by increasing monocyte numbers, induce a pro-regenerative macrophage phenotype, 
increase monocyte HLA-DR expression45 and enhance phagocytic capacity. Multiorgan involvement is 
characteristic of clinical deterioration in ALF and previous reports implicating CSF1 signalling in 
recovery following both kidney and brain injury highlight potential wider benefits of this strategy30, 46. 
The ability to predict patient deterioration, using a marker such as CSF1, prior to meeting the current 
clinical criteria for transplantation (King’s College Hospital criteria) could facilitate the earlier 
stratification of patients with the greatest need. It would be interesting to study the role of CSF1 in 
acute-on-chronic liver failure, where innate immunity may be impaired.  
 
There is mounting evidence for a CSF1 – CCR2 axis in monocyte recruitment with the induction of 
these factors following acute hepatic injury35. The chemokine signalling induced in the liver following 
CSF1-Fc administration was not restricted to the CCR2 receptor, and monocyte extravasation into the 
liver parenchyma was impaired, but not prevented by the CCR2 deficit, suggesting that CSF1-Fc either 
mobilises monocytes from other sources (e.g, the spleen) or overcomes the CCR2-dependence on bone 
marrow release.  
 
In contrast to PH, where the increase in available CSF1 is related to reduced clearance, in acute liver 
toxicity hepatic CSF1 mRNA increased (Fig Suppl. Fig 2c).  Evidence of local production was also 
seen in the liver of patients (Fig Suppl. Fig 2d).  The increased local hepatic CSF1 production may drive 
macrophage accumulation during the early response to injury, when phagocytosis is essential to clear 
dying hepatocytes. As well as the improved clearance of insoluble and infective material to reduce the 
risk of sepsis, macrophages might also promote clearance of circulating tumour cells.  Some of the 
earliest studies of CSF1 treatment demonstrated an impact on tumour metastasis29. CSF1-Fc has already 
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been shown to be safe in pigs24 and the native protein was previously tested by continuous infusion in 
human phase 1 trials  and was well-tolerated47. 
 
In summary, we have shown that elevated serum CSF1 is an important response to liver injury, and 
impairment of this response is associated with poor outcome in acute liver failure. Serum CSF1 response 
following liver injury could be used to stratify patients according to severity and to identify candidates 
for CSF1 therapy.   
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Figure Legends 
Figure 1: Serum CSF1 increases following partial hepatectomy in humans according to extent of resection 
 (a) Serum CSF1 in healthy volunteers and patients undergoing partial hepatectomy to remove cancer. (b) Mean 
serum CSF1 categorised according to extent of resection. (c) Box and whisker plots showing minimum to 
maximum values with patients developing postoperative liver failure overlaid with red dots.  
 
Figure 2: High serum CSF1 level is associated with survival in acute liver failure in humans 
(a) Serum CSF1 level in healthy volunteers and in patients following acetaminophen intoxication on arrival to a 
specialist liver unit (survived n=47; Died/Liver transplantation n=31). (b) Serial CSF1 samples of patients on first 
presentation to hospital following acetaminophen intoxication (n=10/group). (c) Receiver operator characteristic 
curve for serum CSF1, acetyl-HMGB1 (aHMGB1), prothrombin time (PT), ALT (alanine aminotransferase), 
bilirubin and APACHEII score with areas under curve (AUC value) for patients who subsequently survived or 
died/required liver transplantation. (d) Dot plot of serum CSF1 level versus log(serum acetyl-HMGB1) on 
presentation to the specialist liver centre (slope difference: F=0.15, p=0.70; Intercept difference: F=8.03, 
p=0.006). (e) Details of the combined logistic regression model. (f) Example serum values and predicted chance 
of death based on logistic regression involving CSF1 alone (Model 2). 
 
Figure 3: Hepatic enlargement following CSF1R stimulation 
(a) Representative multiphoton image of ex vivo liver (MacGreen mouse Tg(CSF1r-GFP)Hume) (b) Representative 
immunofluorescence images of Csf1r-Mer2iCreJWP x Rosa floxed stop tomato red following induction (c) 
Cytokine/Chemokine array of liver tissue 6 hours following CSF1-Fc treatment versus control (n=4/group). (d) 
Quantification of hepatic F4/80 immunohistochemistry in PBS control treated (n=8) and mice treated with CSF1-
Fc for 2 or 4 days (n=4/group). (e) Quantification of hepatocyte proliferation in control treated mice and at Day 2 
and Day 4 following CSF1-Fc administration (20 HPF/mouse). (f) Serum parameters following 4 days CSF1-Fc 
(grey, hollow circles) or PBS control (black, solid circles) treatment once daily (2-way repeated measures 
ANOVA with Bonferroni post hoc). 
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Figure 4: CSF1 receptor stimulation recruits monocytes and induces macrophage proliferation in 
uninjured mouse liver 
(a) Number of hepatic macrophage populations (F480hi/CD11blo and F480lo/CD11bhi) day 2 following CSF1-Fc 
administration (n=8/group) relative to mean of control group and representative Ly6C profile of F480hi (red) and 
F480lo (blue) populations. (b) Percentage of hepatic macrophage populations expressing markers of proliferation 
(Ki67 and BRDU) day 2 following CSF1-Fc administration relative to mean of control group. (c) Fate tracing 
bone marrow derived monocytes using chimeric mice demonstrating conversion of infiltrating cells to resident 
macrophage phenotype driven by CSF1-Fc. (% cells derived from blood monocytes is based on the ratio of 
chimerism in hepatic populations to chimerism in circulating blood monocytes) (d) Number of hepatic 
macrophage populations Day 2 following CSF1-Fc administration in WT and CCR2-/- mice (n=8/group) with 
representative Ly6C profile of F480hi (red) and F480lo (blue) populations (Solid = CCR2-/-; dotted line = WT) (e) 
Liver weight to body weight ratio following 2 days control (black) or CSF1-Fc administration (grey) in wild type 
and CCR2-/- mice (n=8/group). 
 
Figure 5: CSF1-Fc enhances hepatic phagocytic capacity post partial hepatectomy in mice 
(a) Liver weight to body weight ratio following partial hepatectomy (PH) with CSF1-Fc or control (n=8/group). 
(b) Ki67+ hepatocytes per HPF following PH (n=8/timepoint/group). (c) Number of resident (red) or infiltrating 
(blue) hepatic macrophage populations Day 2 following PH and CSF1-Fc administration. Representative dot plots 
of hepatic macrophage profile and representative Ly6C profile normalised to mode. (d) Hepatic gene expression 
of phagocytic markers MARCO (macrophage receptor with collagenous structure), MSR1 (macrophage 
scavenger receptor 1) and MR (mannose receptor) versus relevant control. (e) Multiphoton image of ex vivo 
Csf1r-eGFP mouse liver following injection of fluorescent microbeads and clearance from the circulation 
following sham or 2/3 PH with control or CSF1-Fc (n=6/group/timepoint)). (f) Net fluorescence liver, spleen, 
lung, kidney and brain Day 2 following PH and CSF1-Fc or control. (n=6 per group). 
 
 
Figure 6: Contribution of hepatic phagocytes to clearance of pathogenic material 
 
(a) Immunohistochemistry of hepatic macrophages (F4/80=green) following isolation by adherence and 
administration of E. coli bioparticles (pHrodoTM) (red). (b) Relative number and percentage of resident 
macrophages phagocytosing E. coli bioparticles (Phrodo). Representative density plots of phagocytic cells in the 
resident macrophage population. (c) Relative number of infiltrating macrophages phagocytosing E. coli  
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bioparticles compared to the mean of the control group with percentage of cells phagocytosing E. coli particles 
according to Ly6C expression status. (d) Pie charts illustrating proportion of phagocytic cells in the liver with bar 
chart showing absolute cell number comparison for resident and infiltrating macrophages, neutrophils and 
eosinophils.  
 
Figure 7: CSF1-Fc and acetaminophen intoxication in mice 
(a) Liver weight to body weight ratio with CSF1-Fc or control. (b) Representative immunoshistochemistry F4/80 
(red) and Ki67 (DAB) at Day 2 and Day 4 following acetaminophen with PBS control or CSF1-Fc.  (c) Hepatic 
expression of phagocytosis associated genes following GW2580 (red), AFS98 (blue) or CSF1-Fc (grey) relative 
to mean of control group (vehicle, rat IgG2a, PBS respectively). (d) Net ex vivo liver fluorescence 15 minutes 
following injection of fluorescent beads. (e) Serum liver associated biochemistry tests at day 3 following 
acetaminophen intoxication and either GW2580 (red), AFS98 (blue) or CSF1-Fc (grey) compared to control 
(vehicle, rat IgG2a, PBS respectively). 
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Figure 4: CSF1 receptor stimulation recruits monocytes and induces macrophage proliferation in 
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Figure 5: CSF1-Fc enhances hepatic phagocytic capacity post partial hepatectomy in mice
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Figure 6: Contribution of hepatic phagocytes to clearance of pathogenic material
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Figure 7: CSF1-Fc and acetaminophen intoxication in mice
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Supplementary Figure 1: Supporting details for partial hepatectomy in humans
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Supplementary Figure 1: Supporting details for partial hepatectomy in humans
(a) Details of patients undergoing partial hepatectomy categorised according to extent of resection
(n=55). (b) Dot plot showing blood loss versus serum CSF1 (no relationship between these
variables). (c) Details of patients developing postoperative liver failure (n=2). Blood loss
according to extent of resection. (d) Hepatic CSF1 gene expression following partial hepatectomy
in mice.
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Supplementary Figure 2: Supporting details for acetaminophen intoxication in humans.
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Supplementary Figure 2: Supporting details for acetaminophen intoxication in humans.
(a) Details of acetaminophen intoxication patients presenting to the specialist liver unit with acute liver
failure grouped according to survivors versus those who subsequently required liver transplantation or died
(patient cohort and acetyl-HMGB1 values as per Antoine et al.24; healthy control data also shown). (b)
Serum CSF1 level in healthy volunteers and in patients following paracetamol intoxication on arrival to a
specialist liver unit grouped according to whether patients subsequently deteriorated to meet the King’s
college criteria or not (KCC no: n=45; KCC yes: n=33). (c) Receiver operator characteristic curves based
on serum CSF1 level in patients according to King’s College Criteria and also patients who subsequently
survived or died/required liver transplantation. (d) Serum CSF1 level according to systemic inflammatory
response score (SIRS) on admission to the tertiary referral hospital with acute liver failure (NB. SIRS
scores available for n=60). (e) Details of patients from first presentation to hospital following
acetaminophen intoxication (n=10 per group; patients randomly selected from patient cohort as per Antoine
et al.24). (f) Immunhistochemistry for the CSF1 protein in explant liver following acetaminophen
intoxication. (g) Hepatic CSF1 gene expression following acetaminophen intoxication in mice (One way
ANOVA with Bonferroni post hoc). (h) Deviance residuals for logistic regression models. (i) Analysis of
deviance comparing combined Log(acetyl-HMGB1) + CSF1 model (Model 1) and CSF1 alone (Model 2).
Symbol Log2(FC) p Value
Adipoq 1.22 1.9E-01
Bmp2 0.04 7.0E-01
Bmp4 0.32 5.9E-01
Bmp6 0.06 9.0E-01
Bmp7 -0.90 9.1E-03
Ccl1 -0.23 2.5E-01
Ccl11 1.32 9.7E-02
Ccl12 4.92 2.8E-02
Ccl17 -0.20 8.2E-01
Ccl19 0.65 9.6E-03
Ccl2 4.34 3.7E-02
Ccl20 -0.11 5.2E-01
Ccl22 -1.39 5.3E-02
Ccl24 0.78 2.6E-01
Ccl3 3.19 1.1E-02
Ccl4 2.61 3.3E-03
Ccl5 -0.26 3.4E-01
Ccl7 6.58 2.9E-02
Cd40lg 0.74 1.9E-01
Cd70 -0.23 2.5E-01
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Csf2 -0.23 2.5E-01
Csf3 -0.23 2.5E-01
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Cxcl5 0.40 4.3E-01
Cxcl9 2.15 8.1E-02
Fasl 1.00 2.8E-01
Gpi1 -1.01 1.5E-01
Hc 1.60 6.5E-02
Ifna2 -0.28 1.9E-01
Ifng 0.97 2.4E-01
Il10 1.23 9.8E-02
Il11 -0.23 2.5E-01
Il12a 0.35 3.7E-01
Il12b 1.62 5.4E-02
Il13 0.05 7.3E-01
Il15 1.09 1.1E-01
Il16 0.06 7.6E-01
Il17a -0.23 2.5E-01
Il17f -0.40 2.0E-01
Il18 1.23 8.2E-02
Il1a 2.21 7.7E-02
Il1b 1.99 6.5E-02
Il1rn 0.77 2.2E-01
Il2 -0.23 2.5E-01
Il21 -0.23 2.5E-01
Il22 -0.23 2.5E-01
Il23a 0.55 2.0E-01
Il24 -0.23 2.5E-01
Il27 0.33 4.6E-01
Il3 -0.23 2.5E-01
Il4 0.56 2.4E-01
Il5 -0.52 4.9E-02
Il6 2.92 2.7E-02
Il7 3.26 3.1E-02
Il9 -0.23 2.5E-01
Lif -0.49 3.5E-02
Lta -0.26 2.1E-01
Ltb -0.91 1.9E-01
Mif -0.40 2.3E-01
Mstn -0.23 2.5E-01
Nodal -0.35 6.5E-01
Osm -0.49 3.1E-01
Pf4 1.30 7.3E-02
Ppbp 1.13 6.2E-01
Spp1 2.36 5.2E-02
Tgfb2 0.11 8.2E-01
Thpo -1.04 2.5E-01
Tnf 1.47 6.5E-03
Tnfrsf11b -0.13 2.5E-01
Tnfsf10 1.07 1.4E-01
Tnfsf11 0.72 2.3E-01
Tnfsf13b 0.36 4.4E-01
Vegfa -0.34 4.1E-02
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Supplementary Figure 3: Continued.
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Supplementary Figure 3: Supporting details for CSF1-Fc treatment of uninjured mice.
d
(a) Array data 6 hours following CSF1-Fc administration in uninjured mice (n=4/group). (b) TUNNEL
immunohistochemistry following PBS control or CSF1-Fc administration (positive control DNAse treated
section). (c) Organ weight relative to mean of control group following 2 days treatment with PBS control
(black solid circles), or CSF1-Fc (grey hollow circles). (d) Representative F4/80 immunohistochemistry
following 2 days treatment with PBS control or CSF1-Fc
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Supplementary Figure 4: Supporting details for CSF1-Fc treatment of uninjured mice.
(a) Representative flow cytometry dot plot of BRDU and Ki67 expression in resident (red) and
infiltrating (blue) macrophages. (b) Representative dual immunohistochemistry F4/80 (green) and
BRDU or Ki67 (red) Day 2 following CSF1-Fc administration or control. (c) Number of hepatic
dendritic cells (CD11c/MHCII +ve), eosinophils and neutrophils in control (black circles) and CSF1-
Fc (grey circles) treated mice relative to mean of control group. (d) Number of Ly6C low, intermediate
and high monocytes in wild type and Ccr2-/- mice following 2 days treatment with CSF1-Fc or PBS
control (two way ANOVA with Bonferroni post hoc). (e) Number of hepatic dendritic cells
(CD11c/MHCII +ve), eosinophils and neutrophils in control (black circles) and CSF1-Fc (grey circles)
treated mice relative to mean of control group.
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Supplementary Figure 5: continued.
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Supplementary Figure 5: Supporting data for partial hepatectomy model
(a) Quantification CYPD2 immunofluorescence (red) per 20x HPF/mouse (control n=8; CSF1-Fc n=7; t
test). (b) Number of mitotic figures and Ki67 positive hepatocytes per high powered field following
following partial hepatectomy and either GW2580, AFS98 or CSF1-Fc administration versus control
(vehicle gavage, rat IgG2a, PBS; n=8/group; 2-way ANOVA comparing intervention with relevant
control, Bonferroni post hoc). (c) Hepatic gene cytokine expression at Day 2 following partial
hepatectomy and either GW2580, AFS98 or CSF1-Fc administration versus control (vehicle gavage, rat
IgG2a, PBS; n=8/group; 2-way ANOVA comparing intervention with relevant control, Bonferroni post
hoc). (d) Hepatic MMP and UPAR (urokinase plasminogen activator) gene expression Day 2 following
partial hepatectomy and either GW2580, AFS98 or CSF1-Fc administration versus control (vehicle
gavage, rat IgG2a, CSF1-Fc; n=8/group; 2-way ANOVA comparing intervention with relevant control,
Bonferroni post hoc). (e) Exvivo fluorescent imaging of organs 1 minute following injection of
fluorescent microbeads into the inferior vena cava. (f) Flow cytometry plots demonstrating bead and cell
gating of blood samples following fluorescent microbead injection into the inferior vena cava. (g)
Representative flow plots of blood sampled from the inferior vena cava at 1 minute and 15 minutes
following injection of fluorescent microbeads into the circulation. Gating strategies including total
fluorescent bead count (“Total beads”) and bead count within blood cellular populations
(“Cells+beads”).
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Supplementary Figure 6: Supporting details for acetaminophen intoxication in mice
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(a) Quantification of area of necrosis and cellular infiltrate at Day 2, 3 and 4 following
acetaminophen intoxication. (b) Hepatic macrophage phenotype D3 following acetaminophen
administration (F4/80+/CD11b- = resident macrophage population; F4/80-/CD11b+ = infiltrating
macrophage population. (c) Serum cytokine array Day 4 following partial hepatectomy and
either PBS control or CSF1-Fc treatment (2-way ANOVA and Bonferroni post hoc ns). (d)
Hepatic albumin gene expression relative to GAPDH comparing control and CSF1-Fc treated
mouse liver (n=8/group; t test ns). (e)Total protein concentration at D3. (f) Serum ALT following
acetaminophen intoxication in control (dotted line) and CSF1-Fc treated (solid line) mice.
Supplementary Figure 7: No evidence of direct hepatocyte effects of CSF1-Fc
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Mouse hepatocyte viability and glutathione depletion assays
Human hepatocyte viability and glutathione depletion assays
a
c
b
(a) MTS reduction assay, LDH leakage assay and GSH content on mouse hepatocytes exposed 
to APAP and increasing concentration of CSF1-Fc showing no dose related effect. (b) MTS 
reduction assay, LDH leakage assay and GSH content on human hepatocytes exposed to APAP 
and increasing concentration of CSF1-Fc showing no dose related effect. (c) Whole liver 
assessment of CYP2E1 expression relative to actin assessed via Western blot and mRNA day 3 
post acetaminophen intoxication with control or CSF1-Fc treatment.
Supplementary Methods 
 
Human serum samples 
Serum samples were blinded and cytokine analysis completed in a random order. Serum CSF1 was 
analysed using the Meso Scale Discovery® CSF1 immunoassay and analysed on a Meso QuickPlex 
SQ120. Serum acetyl-HMGB1 was analysed by mass spectrometry. 
 
Clinical scoring 
King’s college criteria in the context of acetaminophen induced liver failure was defined as arterial 
pH<7.3, international normalized ration (INR) > 6.5, serum creatinine > 300 and the presence of 
encephalopathy1. The Systemic Inflammatory Response Criteria (SIRS) were met when 2 or more of 
the following occurred: body temperature >38°C or < 36°C; heart rate >90 beats per minute; respiratory 
rate >20 breaths per minute; white blood cell count >12,000/cf mm or <4,000/cf mm2. APACHE2 score 
was calculated as previously described3. 
 
Reagents 
CSF1-Fc is a conjugate of porcine CSF1 with the Fc region of porcine IgG1A (43.82kD total) produced 
by Zoetis for D. Hume (UK patent application GB1303537.1). Porcine CSF1 is equally active in mice4.  
The Fc conjugate provides increased circulating half-life.  CSF1-Fc did not exhibit any endotoxin like 
activity in murine BM-derived macrophages5. CSF1 receptor blockade was induced by the CSF1R 
tyrosine kinase inhibitor, GW2580 (160mg/kg suspended in 0.5% hydroxypropylmethylcellulose and 
0.1% Tween 805, LC laboratories), or using the antibody AFS98 produced by Sudo et al. 6, and provided 
by BioServ UK.  CSF1-Fc, GW2580 and AFS98 were administered immediately following 2/3 partial 
hepatectomy or 12 hours following acetaminophen intoxication (point of maximal injury7). 
 
 
 
Collection of mouse tissues 
Mice were culled via CO2 inhalation and following a midline laparotomy blood was aspirated from the 
inferior vena cava for serum analysis.  Mice were perfused through the inferior vena cava and viscera 
excised and weighed. Viscera were either fixed in 4% formalin for immunohistochemistry, placed in 
RNA later® (Life Technologies), or placed in PBS for flow cytometry.  
 
Immunohistochemistry 
Three µm sections of formalin-fixed tissue were used for immunostains. Ki67, BRDU and CYPD2 
required heat mediated antigen retrieval with 0.01M sodium citrate pH 6.0 for 10 minutes. Primary 
antibodies were used at the following dilutions: Ki67 (Leica) 1:500, BRDU (Abcam) 1:100, F4/80 
(clone CI:A3-I, Biolegend) 1:100, CYPD2 (Abcam) 1:100. Appropriate secondary antibody was 
applied at a 1:250 dilution. Dual immunohistochemistry with F4/80 and BRDU or Ki67 was performed 
by first developing F4/80 using the Tyramide signal amplification system (PerkinElmer®) with 
subsequent heat mediated antigen retrieval followed by BRDY or Ki67 staining. Ki67 and F4/80 dual 
immunohistochemistry was also performed by developing F4/80 with an alkaline phosphatase substrate 
kit (red, Vector) and following heat mediated antigen retrieval Ki67 was developed with 3,30-
diaminobenzidine (Dako). Stained slides were blinded and images taken on the Nikon Eclipse E600. 
For image quantification of F4/80 staining 20 non overlapping images were photographed at x200. The 
extent of DAB staining quantified using image analysis software (Adobe Photoshop CS6). For CYPD2 
quantification images were quantified using image analysis software (Adobe Photoshop CS6). For Ki67 
quantification 20 serial non overlapping images were photographed at x400 then hepatocytes identified 
by assessment of morphology. 
 
Flow cytometry 
Liver was digested in 2mg/ml collagenase D (Sigma Aldrich) at 37degC for 30minutes then passed 
through a 100μm filter. 7 minute 50G spin to remove hepatocytes. Further purification of 
nonparenchyaml cells using 30% percoll® (Sigma) gradient. Cell stained with fixable viability dye 
eFluor 780® then incubated with Fc block (TrustainfcX™, Biolegend) prior to staining with CD45 
(clone:30F11, AF700, Biolegend), F480 (clone:BM8, PECy7, Biolegend), CD11b (clone:RM208, 
FITC, Invitrogen), Ly6C (clone:HK1.4, PerCP/Cy5.5, Biolegend), dump gate (PE: CD3 (clone:17A2, 
PE, Biolegend, CD19 (clone:6D5, PE, Biolegend), Siglec F (clone:E502440, PE, BD Biosciences), 
Ly6G (clone:IA8,PE, BD Biosciences). For proliferation assay cells were fixed and permeablised using 
BD Pharminogen BRDU flow kit then stained with antiBRDU (FITC, BD Pharminogen) and Ki67 
(eF660, eBioscience). Flow cytometry performed using the LSR Fortessa. 
 
Quantification of Messenger RNA 
Quantification of messenger RNA (mRNA) Levels by Real-Time Reverse-Transcription Polymerase 
RNA extraction kits (Qiagen) were used to extract RNA from whole tissue. Predesigned validated 
primer sets for MARCO (macrophage receptor with collagenous structure), MSR1 (macrophage 
scavenging receptor 1), MR (mannose receptor), Il6, OSM (oncostatin M), TNF (tumour necrosis 
factor), IFNg (interferon gamma), Il10 and GAPDH were purchased from Qiagen (Qiagen Quantitect 
Primers). Quantitative real-time PCR was performed using Express SYBR Green (Qiagen, UK). Gene 
expression was calculated relative to GAPDH for each sample. Gene array at 6 hours following CSF1-
Fc administration was performed using Cytokine and Chemokine array RT2 Profiler PCR arrays and 
analysed using the online RT2 profiler PCR Array Data Analysis (Version 3.5, Qiagen, UK) and 
presented by Volcano plot. Affymetrix Mouse gene 1.1 ST Array data were accessed from the Gene 
Expression Omnibus website and analysed using GEO2R with Benjamini & Hochberg (False discovery 
rate) correction applied to the entire data series.   
 
Phagocytosis assay 
Under 2% isofluorane anaesthesia the inferior vena cava was cannulated and 100μl of red fluorescent 
bead solution (1:5 Latex beads 1.0μm, fluorescent red, SIGMA-ALDRICH®) infused through the 
cannula (1:2 solution for assay following paracetamol injury). Ex vivo fluorescent quantification was 
performed at one minute following bead injection and 15mls 0.9% NaCl flush (see Supplementary 
Figure 5a). For assessment of bead clearance from the circulation 20mcl of blood was removed from 
the cannula every two minutes starting from 1 minute post injection for 15 minutes and immediately 
fixed (300μl FACS-Lyse, BD Biosciences). After the 15 minute timepoint mice were perfused with 
15mls 0.9% saline through the IVC cannula with portal vein outflow. Organs were then removed (Liver, 
spleen, lungs, kidney, brain) and imaged using a Kodak In-Vivo Multispectral FX image station 
(Excitation: 550nm; Emission: 600nm; Exposure 1 sec; f-stop 2.8). Subsequently blood samples were 
analysed using a LSR-Fortessa™ flow cytometer (BD Biosciences) with fluorescent beads detected on 
the blue channel (B695/40) by a 1 minute sample collection on low flow rate setting. Multiphoton 
imaging was performed using a Zeiss LSM7 MP with Coherent Chameleon Ti:Sa laser.  
 
Mouse Serum Analyses 
Serum biochemistry assays were performed using commercially available kits by a biochemist, 
including alanine aminotransferase (ALT; Alpha Laboratories), alkaline phosphatase (Alk phos; Roche 
Diagnostics), total bilirubin (bili; Alpha Laboratories Ltd), albumin (Alb; Alpha Laboratories). Total 
serum protein was analysed using the Bradford assay as previously described8. Serum cytokines and 
chemokines were analysed using MILLIPLEX® mouse cytokine/chemokine array (Merck-Millipore) 
in collaboration with a Merck-Millipore biomarker specialist.  
 
Hepatocyte metabolic and toxicity assays 
Human and mouse hepatocytes were isolated from liver tissue as previously described9, 10. Glutathione 
(GSH) depletion assay, MTS reduction assay and LDH leakage assay were performed on human and 
mouse hepatocytes as previously described10. 
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